Pyxis Oncology (NASDAQ:PYXS) Upgraded by Wells Fargo & Company to Strong-Buy Rating

Pyxis Oncology (NASDAQ:PYXS) was upgraded by investment analysts at Wells Fargo & Company to a “strong-buy” rating in a report issued on Monday,Zacks.com reports.

A number of other brokerages also recently commented on PYXS. Wedbush began coverage on Pyxis Oncology in a research report on Tuesday, May 5th. They set an “outperform” rating and a $6.00 price objective for the company. Wall Street Zen cut shares of Pyxis Oncology from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Leerink Partners decreased their price target on shares of Pyxis Oncology from $9.00 to $7.00 and set an “outperform” rating for the company in a research note on Thursday, July 2nd. Finally, Weiss Ratings cut shares of Pyxis Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 30th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $7.50.

Pyxis Oncology Price Performance

PYXS opened at $3.04 on Monday. Pyxis Oncology has a 12 month low of $0.97 and a 12 month high of $5.55. The stock has a market capitalization of $192.58 million, a price-to-earnings ratio of -2.32 and a beta of 1.31. The business has a fifty day moving average price of $2.28 and a 200 day moving average price of $1.88.

Pyxis Oncology (NASDAQ:PYXS) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.02). On average, research analysts anticipate that Pyxis Oncology will post -1.19 earnings per share for the current year.

Institutional Trading of Pyxis Oncology

Institutional investors have recently bought and sold shares of the business. Maia Wealth LLC acquired a new position in shares of Pyxis Oncology during the 4th quarter worth about $25,000. Engineers Gate Manager LP acquired a new stake in shares of Pyxis Oncology during the 4th quarter worth about $26,000. Fox Run Management L.L.C. acquired a new stake in shares of Pyxis Oncology during the 4th quarter worth about $26,000. XTX Topco Ltd purchased a new stake in Pyxis Oncology during the second quarter worth approximately $40,000. Finally, LPL Financial LLC lifted its stake in Pyxis Oncology by 150.7% during the fourth quarter. LPL Financial LLC now owns 35,102 shares of the company’s stock worth $40,000 after purchasing an additional 21,100 shares during the last quarter. 39.07% of the stock is owned by hedge funds and other institutional investors.

Pyxis Oncology Company Profile

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.